Carboxy methyl cellulose

PreclinicalSmall molecule

MMinia University

Carboxy methyl cellulose is one of 4 small molecule programs targeting Corneal Ulcer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Corneal UlcerActive, not recruiting

Corneal UlcerPreclinical

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Corneal Ulcer

#DrugCompanyPhaseTrials

Levaquin

Vivitrol

1 3

Specific Treatment

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 4

Carboxy methyl cellulose

MMinia University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Corneal Ulcer1 trial

The Use of Naltrexone Hydrochloride to Promote Healing in Patients With Resistant Non-infectious Corneal Ulcer

Completed·MMinia University·N/A·NCT05924893·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Carboxy methyl cellulose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carboxy methyl cellulose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carboxy methyl cellulose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Minia University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMinia University

Carboxy methyl cellulose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Corneal Ulcer1 trial

References

Drug Info

Quick Facts

Related News